29 results about "Levocarnitine" patented technology

The invention provides a pharmaceutical composition which comprises a compound shown as a formula (I) or pharmaceutically acceptable salts thereof, and acetyl levocarnitine or salts thereof, and application of the pharmaceutical composition in preparation of drugs for treating diabetic peripheral neuralgia. # imgabs0 #

The invention discloses a method for determining dextrocarnitine in a levocarnitine product by using high performance liquid chromatography, and the chromatographic conditions are as follows: cellulose-tri-(3, 5-dimethyl phenyl carbamate) is used as a filler for a chromatographic column, a hexafluorophosphate buffer solution-acetonitrile is used as a mobile phase, the volume ratio is 77: 23-69: 31, the column temperature is 15-25 DEG C, the flow velocity is 0.3-0.5 ml / min, and the detection wavelength is 246nm. The method disclosed by the invention can be used for rapidly and accurately detecting the dextrocarnitine in the levocarnitine product and calculating the content of the dextrocarnitine, is simple to operate and good in reproducibility, can better realize quality control of the levocarnitine preparation and an intermediate product thereof, and provides guarantee for synthesis and preparation process optimization.

The invention belongs to the technical field of medicine detection, and particularly relates to a method for determining enantiomers in a levocarnitine intermediate by gas chromatography. The method for determining the enantiomer in the levocarnitine intermediate by the gas chromatography comprises the following steps: taking a capillary column which takes dimethyl polysiloxane bonded with cyclodextrin as a stationary liquid as a chromatographic column; the method comprises the following steps: dissolving and diluting a test product (R)-4-chloro-3-hydroxy ethyl butyrate by using ethyl acetate, and deriving by adding acetic anhydride and pyridine to prepare a test product solution; and injecting the test solution into a gas chromatograph, recording a chromatogram, and calculating the content of the enantiomer (S)-4-chloro-3-hydroxybutyric acid ethyl ester in the levocarnitine intermediate (R)-4-chloro-3-hydroxybutyric acid ethyl ester according to an area normalization method. The method for determining the enantiomer in the levocarnitine intermediate by the gas chromatography provided by the invention is accurate and fast in detection, and provides a basis for quality control of levocarnitine.

The present invention discloses a preparation method of a levocarnitine intermediate. It uses S-epichlorohydrin as the starting material, first undergoes an amination reaction with trimethylamine hydrochloride to obtain L-3-chloro-2-hydroxypropyltrimethylammonium chloride, and then undergoes a cyanation reaction with sodium cyanide to obtain the levocarnitine intermediate L-3-cyano-2-hydroxypropyltrimethylammonium chloride; after the amination reaction is completed, a complexing agent is used to treat the reaction system, and the complexing agent is preferably phytic acid; after the cyanation reaction is completed, an adsorbent is used to treat the reaction system; the adsorbent is preferably activated carbon. The method of the present invention can significantly improve the color of the L-quaternary ammonium salt solution by adding a complexing agent for treatment after the amination reaction, and further can significantly improve the color of the L-nitrile compound and reduce its impurity content; the method of the present invention can further improve the color of the L-nitrile compound and further reduce the impurity content of the L-nitrile compound by adding an adsorbent for treatment after the cyanation reaction.

The invention discloses a kind of preparation method of L-carnitine, comprise the steps:Trimethylamine is added in the mixed solution of NaOH, water and organic solvent, R-4-chloro-3-hydroxybutyric acid ethyl ester is slowly dripped under cryogenic conditions, stirring reaction under identical temperature conditions after dropping and finishing;Raise temperature, continue reaction;Hydrochloric acid is dripped into reaction solution and adjusted pH value until reaction solution pH value is neutral, obtain the reaction solution containing L-carnitine;Desalt the reaction solution containing L-carnitine by electrodialysis, distillation and water removal, obtain L-carnitine. The scheme provided by the application is simple to operate, mild condition, and greatly reduces the reaction time simultaneously, is suitable for industrialized production, and by screening appropriate organic solvent and mixing with water to reduce freezing point to lower reaction temperature, suppresses the generation of impurities, thus improves product yield.

A botulinum toxin protein composition comprising a botulinum toxin protein and a protein stabilizer, the protein stabilizer being selected from either an amino acid or an amino acid-like compound, the amino acid being selected from one or more of L-histidine, L-glycine, L-arginine, L-methionine, and L-lysine, and the amino acid-like compound being levocarnitine, the botulinum toxin protein composition can be applied as a liquid formulation in the medical and cosmetic fields, and the activity of the botulinum toxin protein can be stably maintained in a liquid state.

Disclosed is a levocarnitine and trimetazidine bilayer tablet. The present disclosure adopts a bilayer structure of the levocarnitine and trimetazidine dihydrochloride, and a contact area between the levocarnitine layer and the air can be greatly reduced by covering one side of a surface of the levocarnitine layer with the trimetazidine dihydrochloride layer, such that the problem of hygroscopicity of the levocarnitine layer can be effectively inhibited, and the effective amount of the drug is increased. Moreover, the preparation process in the present disclosure is easy to operate and suitable for actual production and use, as well as is capable of solving the problem of content uniformity well, and the stability of the bilayer tablet is effectively improved.

The invention discloses a method for determining related substances in L-carnitine and its injection by high performance liquid chromatography, wherein the mobile phase used is a potassium dihydrogen phosphate buffer-acetonitrile mixed solution with a pH of 4.0 to 6.0; a diluent is used to prepare the solution; the diluent is a mobile phase with a pH of 2.0 to 3.5 adjusted by a hydrochloric acid solution; and the volume ratio of potassium dihydrogen phosphate buffer to acetonitrile in the mobile phase is 35:65. The invention finally finds through a large number of experiments that the use of a mobile phase with a certain pH as a diluent to prepare various solutions can effectively avoid the interference of a 2-5min solvent peak, so that the content of L-carnitine can be accurately calculated for L-carnitine that does not contain 2-5min impurities in the sample itself, and the content of L-carnitine and 2-5min impurities can be accurately calculated simultaneously for L-carnitine that contains 2-5min impurities in the sample itself.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The invention provides a levocarnitine raw material medicine production screening device with a material conveying mechanism, and relates to the technical field of levocarnitine raw material medicine production device.The levocarnitine raw material medicine production screening device comprises a supporting frame, a flow guide pipe, a spring, a first-stage filter sieve and a second long plate, the flow guide pipe and a first air inlet connector are installed on the side face of the supporting frame, and the spring is arranged above the supporting frame; a first-stage filter sieve, a second-stage filter sieve and a third-stage filter sieve are sequentially installed above the spring, first dust collection connectors are installed above the first-stage filter sieve, the second-stage filter sieve and the third-stage filter sieve, a cover plate is arranged above the third-stage filter sieve, a first motor, a conveying pipe and an auger are installed above the cover plate, and a second motor is installed above the first motor. According to the equipment, the surface of the outer side of a first dust collection connector is sleeved with threads, a hose can be used as a flow guide ventilation part, and the equipment is light in mass, low in cost and high in reliability; and enough discharging air pressure is provided for equipment.

The present invention relates to the technical field of drug improvement, and specifically provides an injection containing L-carnitine and a preparation method thereof, wherein the injection containing L-carnitine comprises the following raw materials: L-carnitine with a mass fraction of 16-22%, coenzyme Q10 with a mass fraction of 1.7-2.8%, a Chinese medicine extract with a mass fraction of 27-36%, and normal saline to make up the remaining mass fraction. The present invention further experiments on the basis of the combination of L-carnitine and Chinese medicine mentioned in the background technology, on the one hand, expands the types of Chinese medicines that can be used in combination and forms a synergistic compound, and on the other hand, finds that the injection of L-carnitine, coenzyme Q10 and Chinese medicine extract after mixing is better than the injection of each separately, and it is speculated that coenzyme Q10 and Chinese medicine extract improve the stability of L-carnitine, and the coordination effect of the mixed injection is more obvious than the injection of each separately.

The present invention belongs to the technical field of organic synthesis of pharmaceutical compounds, and in particular to a synthesis process of L-carnitine. The following steps are included: 4-chloroacetoacetic acid ethyl ester is dissolved in acetone, and then an acid reagent is added to adjust the pH to 4-5, and a mixed solution containing 4-chloroacetoacetic acid is obtained by vacuum distillation; the mixed solution containing 4-chloroacetoacetic acid is mixed and stirred with a trimethylamine aqueous solution to form a reaction solution, and the reaction solution and an alkali reagent are mixed to obtain a mixed solution containing trimethylammonium sodium acetoacetate; the mixed solution containing trimethylammonium sodium acetoacetate is adjusted to pH 6.4-6.8 with a potassium phosphate buffer, and then ketoreductase, coenzyme and cosolvent are added to the mixed reaction to obtain L-carnitine. The present invention uses 4-chloroacetoacetic acid ethyl ester as the starting synthetic material, first acidifies it, and then reacts with trimethylamine in the trimethylamine aqueous solution to form trimethylammonium sodium acetoacetate, and trimethylammonium sodium acetoacetate is subjected to the reduction hydrogenation of ketoreductase and coenzyme to obtain L-carnitine.

The invention discloses a levocarnitine refining method which comprises the following steps: mixing and heating a levocarnitine crude product and a recrystallization solvent until the levocarnitine crude product and the recrystallization solvent are completely dissolved, then cooling and crystallizing, and carrying out suction filtration, washing and drying to obtain high-purity levocarnitine, wherein the recrystallization solvent comprises a first solvent and a second solvent; the first solvent is at least one of tetrahydrofuran, acetone, acetonitrile, n-butyl alcohol, ethyl acetate and N, N-dimethylformamide; the second solvent is at least one of water and ethanol; the mass ratio of the first solvent to the second solvent is 1: (0.2-8). According to the method disclosed by the invention, 4-(trimethyl ammonium) butyl-2-olefine acid inner salt and 4-(trimethyl amino)-2-butenamide impurities with similar structures in the levocarnitine crude product can be effectively removed, the purity of the product reaches 99.5% or above, the product meets the pharmacopoeia standard, and the quality of the product has obvious competitiveness.

The invention provides levocarnitine chewable tablets as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The levocarnitine chewable tablet disclosed by the invention is prepared from levocarnitine, modified hydroxypropyl methyl cellulose, microcrystalline cellulose PH102, sodium carboxymethyl starch, quaternized chitosan, sodium caprate, sulfobutyl ether-beta-cyclodextrin, mannitol, sorbitol, sodium stearyl fumarate and superfine silica powder. The modified hydroxypropyl methyl cellulose is prepared from hydroxypropyl methyl cellulose through citric acid crosslinking and 1, 2-propylene glycol carbonate reaction in sequence, initial release and later slow release of the levocarnitine can be controlled, and long-acting release of the levocarnitine is achieved. The levocarnitine chewable tablet can realize stable release of levocarnitine and maintain stable blood concentration, has palatability and high bioavailability, is especially suitable for patients with dysphagia, and has important clinical value.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a levocarnitine tablet and a preparation method thereof. The levocarnitine tablet comprises an active component levocarnitine or a derivative thereof or a medicinal salt thereof, polyvinylpyrrolidone, mixed microcrystalline cellulose and a lubricant, and the levocarnitine tablet after mixed tabletting has remarkable moisture absorption resistance.

The invention provides an anti-aging nutrition supporting agent and application thereof. The core active ingredients of the nutrition supporting agent comprise levocarnitine, D-ribose, coenzyme Q10, glycine, taurine and ascorbic acid. All the components of the nutrition supporting agent have a synergistic effect, so that the movement balance, coordination, endurance and cognitive functions of old people can be remarkably improved.

The invention provides a preparation and purification method of (S)-3-chloro-2-hydroxypropyl trimethyl ammonium chloride, which comprises the following steps: dissolving trimethyl hydrochloride in methanol to obtain a solution, adding S-epichlorohydrin into the solution for reaction, partially or completely removing a reaction solvent after the reaction is finished, and then adding dichloromethane for pulping to remove impurities. According to the technical scheme, high-temperature distillation treatment is not needed, byproducts are few, especially biquaternary ammonium salt impurities grow slowly, hydrolysis impurities and basic toxic impurities such as S-epichlorohydrin can be effectively removed, and medication safety and effectiveness of the levocarnitine product are guaranteed.

This invention belongs to the field of pharmaceutical formulations, specifically relating to a levocarnitine oral gel and its preparation method. This invention discloses a stable levocarnitine oral gel composition comprising levocarnitine, a gel matrix, an alkali metal salt, and sodium polyacrylate. The stable levocarnitine oral gel disclosed in this invention is easy to swallow, has good medication adherence, does not undergo dehydration and shrinkage during the observation period, has stable product quality, good safety, and is convenient to carry and use; the process is simpler, with high production efficiency and lower risk, making it suitable for large-scale industrial production.

The invention belongs to the technical field of chemistry, and particularly relates to a method for purifying levocarnitine. The crude product solution is effectively filtered through the composite membrane, various different impurities can be effectively removed through cooperation of the membranes, multiple purification procedures are avoided, meanwhile, purification can be effectively conducted through the temperature and pressure in cooperation with the corresponding pressure, and the purity reaches 99% or above.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a pharmaceutical composition in the treatment of moderate fatty liver. This invention provides a combination of levocarnitine and trimetazidine, which, through the synergistic effect of levocarnitine and trimetazidine, treats moderate non-alcoholic fatty liver from the perspective of fat and glucose metabolism, thereby achieving its application in the treatment of moderate fatty liver.

The invention relates to the use of L-carnitine or its derivatives in preparing a medicine for treating constipation. The L-carnitine derivatives are selected from acetyl-L-carnitine, propionyl-L-carnitine, and their pharmaceutically acceptable salts and pharmaceutically acceptable salts of L-carnitine. The medicine comprises an oral preparation and an injection.

To provide a tablet that is of a size suitable for a patient and has high storage stability even with a high content of levocarnitine of a free body.SOLUTION: A film coating tablet has an uncoated tablet containing levocarnitine (free body) and porous calcium silicate in a mass ratio of 1:0.25-2, and a film coating layer that coats the uncoated tablet.SELECTED DRAWING: None

The application discloses a method for determining potential genotoxic impurities in levocarnitine by GC-MS, comprising the following steps: preparing a test sample solution: taking 0.2-3g of levocarnitine, accurately weighing, placing in a centrifugal tube, adding 1-2ml of water, shaking to dissolve the sample, adding 5ml of acetone, first shaking to extract, then sealing and centrifuging, and taking the supernatant; preparing a control sample solution; respectively performing GC-MS detection on the control sample solution and the test sample solution, and determining the content of 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in the levocarnitine by an external standard method. The application adopts GC-MS to determine the potential genotoxic impurities 2,3-dichloro-1-propanol and 1,3-dichloro-2-propanol in levocarnitine, and has high separation efficiency, fast analysis speed and high detection sensitivity, and can effectively control the quality of the levocarnitine.

The invention relates to the technical field of medical instruments, and discloses a composite hyaluronic acid beauty fluid formula, which comprises 2 ml of levocarnitine, 2 ml of furosemide, 2 ml of gastrodin, 1 ml of dexamethasone, 3 ml of triamcinolone acetonide, 1 ml of auxin, 3 ml of lidocaine, and 100 ml of saline water. Through two-way regulation and control, tissue regeneration is not stimulated, the healing property is high, and the problem caused by excessive filling of regenerative materials can be rapidly solved.

The invention relates to a traditional Chinese medicine compound composition for treating oligoasthenospermia and a preparation method thereof. The traditional Chinese medicine compound composition comprises a traditional Chinese medicine component, a western medicine component and an auxiliary material component, the traditional Chinese medicine components comprise the following components: radix astragali, radix ophiopogonis, radix morindae officinalis, herba epimedii, radix polygoni multiflori preparata, semen cuscutae and rhizoma polygonati preparata; the western medicine component is levocarnitine; the auxiliary material components comprise the following components: a zinc-containing component, a selenium-containing component and vitamin E. The traditional Chinese medicine composition contains traditional Chinese medicinal materials such as astragalus membranaceus, radix ophiopogonis and morinda officinalis, Western medicine components and auxiliary material components are cooperatively added, the curative effect on oligoasthenospermia is remarkably improved through the synergistic effect of the multiple components, and the traditional Chinese medicine composition has good market application prospects.

The present invention relates to the technical field of pharmaceutical and chemical synthesis, and particularly to an industrial preparation method of levocarnitine. The method comprises the following steps: adding an Escherichia coli engineered bacterium cell containing carbonyl reductase and glucose dehydrogenase, anhydrous glucose, and coenzyme into a buffer salt solution, dropping ethyl 4-chloroacetoacetate for reaction, and obtaining ethyl (R)-4-chloro-3-hydroxybutyrate through extraction, concentration under reduced pressure, and high-vacuum distillation; dropping ethyl (R)-4-chloro-3-hydroxybutyrate into an aqueous solution of trimethylamine in the presence of an inorganic base, keeping the temperature for reaction, adjusting the pH with an acid first and then with a base after the reaction ends; and obtaining the levocarnitine compound through electrodialysis for desalting. The present invention uses a whole-cell catalysis method, which has stronger adaptability; does not use a cosolvent, is green and environmentally friendly, has little influence on enzyme activity, and has higher optical purity of the product. By changing the addition mode of the intermediate, the reaction is more complete and the yield is higher. The electrodialysis for desalting has good effect, high efficiency, and is more suitable for industrialization.

The utility model relates to the technical field of food processing, in particular to an L-carnitine coffee powder semi-finished product deslagging device which comprises a material receiving box, a round hole is formed in the center of the top of the material receiving box, a material receiving frame is installed in the box, and a first supporting frame is fixed to the top of the material receiving box. A motor is fixedly installed at the top of the supporting frame through a supporting plate, an output shaft of the motor is connected with a connecting shaft, and a feeding barrel is slidably installed on the connecting shaft. According to the device, the motor drives the limiting barrel to rotate, and the design of the upper and lower slope rings is utilized, so that the feeding barrel can generate regular up-down vibration, coffee powder can smoothly pass through the screening hopper, large particles and other impurities are effectively removed, the fineness and purity of the coffee powder are improved, meanwhile, the automatic screening process is achieved, manual intervention is reduced, and the screening efficiency is improved. The labor intensity is reduced, and the production efficiency is improved.

This invention belongs to the pharmaceutical field, specifically relating to a compound pharmaceutical preparation for treating chronic uric acid nephropathy and its application. This invention provides a compound pharmaceutical preparation for treating chronic uric acid nephropathy, which is a tablet composed of levocarnitine and trimetazidine in a certain proportion. The levocarnitine and trimetazidine compound preparation can significantly improve renal function in patients with chronic uric acid nephropathy and protect against kidney damage.

The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a L-carnitine liquid preparation and a preparation method thereof. The L-carnitine liquid preparation of the present invention contains L-carnitine, ectoine and / or hydroxyectoine, a pH regulator and water, wherein the weight ratio of L-carnitine to ectoine and / or hydroxyectoine is 100:(7-40). Through preparation optimization, the stabilizing effect of ectoine and / or hydroxyectoine is utilized to improve the stability of the L-carnitine liquid preparation, and the impurity I and the total impurity content, especially the impurity content during the heat treatment process, can be reduced. The L-carnitine liquid preparation of the present invention has a simple configuration process, a wide process tolerance temperature range, and is suitable for large-scale industrial production.